Galderma Presents Phase 3 Data on Relfydess Neuromodulator at TOXINS 2026, Demonstrating Superior Efficacy and Duration
核心洞察
Galderma presented phase 3 data on Relfydess (搜索) (relabotulinumtoxinA) at TOXINS 2026, showing >98% responder rates for frown lines (搜索) and >88% for crow's feet (搜索) at one month post-treatment.
The ready-to-use liquid neuromodulator demonstrated sustained efficacy with median 24-week duration before return to baseline severity for both facial indications.
New head-to-head diffusion studies showed Relfydess (搜索) has similar and limited diffusion profiles compared to onabotulinumtoxinA in preclinical models.
Galderma presented compelling phase 3 clinical data on its innovative neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain, reinforcing the company's leadership position in injectable aesthetics. The presentations focused primarily on Relfydess (搜索) (relabotulinumtoxinA), the first and only ready-to-use liquid neuromodulator designed with proprietary PEARL Technology, alongside data on Dysport (abobotulinumtoxinA).
Phase 3 Efficacy Results Demonstrate Superior Performance
The centerpiece of Galderma's presentations included encore post-hoc subgroup analyses from pooled phase 3 READY program data evaluating Relfydess (搜索) in moderate-to-severe glabellar lines (搜索) (frown lines (搜索)) and lateral canthal lines (搜索) (crow's feet (搜索)). The results demonstrated exceptional efficacy rates, with more than 98% of patients treated for glabellar lines and over 88% treated for crow's feet assessed by investigators as responders at one month post-treatment.
Particularly noteworthy was the sustained duration of effect, with both patients and investigators reporting a median time of 24 weeks before return to baseline severity for both facial indications. This six-month duration was observed regardless of prior neuromodulator exposure, suggesting consistent performance across treatment-naïve and previously treated populations.
"The READY phase 3 analyses presented at TOXINS 2026 reinforce Relfydess (搜索) as a high-performance neuromodulator designed for fast onset, sustained results that last, and ease of use," said Sachin M. Shridharani, MD, FACS, board-certified plastic surgeon and founder of Luxurgery in New York. "The clinical studies show improvements in both frown lines (搜索) and crow's feet (搜索), as early as day one, as well as duration for 6 months, with up to 75% of patients not returning to baseline."
PEARL Technology Delivers Molecular Innovation
Relfydess (搜索) distinguishes itself through its proprietary PEARL Technology, designed to preserve molecule integrity and deliver a highly active, complex-free molecule. Unlike lyophilized botulinum toxin products requiring reconstitution, Relfydess is optimized for simple volumetric dosing without preparation, potentially reducing variability and increasing ease of use for practitioners.
The technology enables up to 39% of patients to see effects from day one, with up to 75% of patients maintaining improvements for six months. Bill Andriopoulos, PhD, Head of Global Medical Affairs at Galderma, emphasized the innovation's significance: "Through our proprietary PEARL Technology, we've introduced a novel approach designed to preserve molecule integrity to deliver fast and sustained results and expand what is scientifically possible in a ready-to-use liquid formulation."
Safety Profile Confirmed Through Comparative Studies
New data presented at the conference included results from an in vivo head-to-head diffusion study comparing Relfydess (搜索) with onabotulinumtoxinA in a rat model. The findings showed similar and limited diffusion profiles between the two agents, addressing important safety and precision considerations in neuromodulator use. This data supports Relfydess' favorable safety profile alongside its rapid onset and sustained efficacy.
Dysport Demonstrates High Patient Satisfaction
Galderma also presented data on Dysport, focusing on patient and practitioner satisfaction following treatment of frown lines (搜索). Results from a real-world study conducted in China evaluating repeated Dysport treatment cycles showed patient satisfaction rates reaching up to 100% three weeks after the third treatment cycle, demonstrating the product's consistent performance in diverse populations.
Educational Initiative Advances Scientific Understanding
Beyond data presentations, Galderma hosted a dedicated Relfydess (搜索) Masterclass led by expert speakers Dr. Joanna Czuwara and Dr. Birgit Blessmann-Gurk. The educational session delved into clinical data, real-world treatment experience, and the science behind Relfydess' PEARL Technology, featuring insights into its rapid onset, long duration, and scientific differentiation principles.
Market Leadership Position Strengthened
The comprehensive data presentations at TOXINS 2026 underscore Galderma's unique position as the only company with a portfolio of neuromodulators. As stated by Baldo Scassellati Sforzolini, MD, PhD, Global Head of R&D at Galderma: "As the only company with a portfolio of neuromodulators, we're building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitioners."
The company's integrated capabilities spanning discovery, research, development, manufacturing, and marketing position it to maintain leadership across all aspects of injectable aesthetics. With Relfydess (搜索) having received marketing authorization in several markets and serving as an investigational drug product in the U.S., Galderma continues to expand its global footprint in the rapidly growing dermatology market.